Compare PPSI & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | BYSI |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 35.8M |
| IPO Year | 2008 | 2016 |
| Metric | PPSI | BYSI |
|---|---|---|
| Price | $2.96 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 56.9K | ★ 1.9M |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,627,000.00 | N/A |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $22.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.75 | N/A |
| 52 Week Low | $2.35 | $0.73 |
| 52 Week High | $6.29 | $2.44 |
| Indicator | PPSI | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 35.32 |
| Support Level | $2.75 | N/A |
| Resistance Level | $3.36 | $1.84 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 26.00 | 18.92 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets. The Company launched two new product platforms namely, PRYMUS, a new, mobile on-site power system concentrating on customers with requirements of 1-10 megawatts of mobile power and PowerCore, a residential and small commercial based primary generator system integrating a DC fast charger into one solution.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.